UY38278A - Agentes inhibidores de ask1 - Google Patents
Agentes inhibidores de ask1Info
- Publication number
- UY38278A UY38278A UY0001038278A UY38278A UY38278A UY 38278 A UY38278 A UY 38278A UY 0001038278 A UY0001038278 A UY 0001038278A UY 38278 A UY38278 A UY 38278A UY 38278 A UY38278 A UY 38278A
- Authority
- UY
- Uruguay
- Prior art keywords
- ask1
- inhibiting agents
- compounds
- disorders
- formulas
- Prior art date
Links
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 title 1
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporcionan compuestos de fórmula (I): que incluyen compuestos de las Fórmulas (II), (III) y (IV), donde X, R1, R2, R3 y n son tal como se definen en la presente, y sales farmacéuticamente aceptables de estos, y métodos para su uso y producción. Estos compuestos pueden ser útiles, por ejemplo, en el tratamiento de trastornos que responden a la inhibición de la cinasa reguladora de las señales de apoptosis 1 (ASK1).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862690674P | 2018-06-27 | 2018-06-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY38278A true UY38278A (es) | 2020-01-31 |
Family
ID=67254023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001038278A UY38278A (es) | 2018-06-27 | 2019-06-26 | Agentes inhibidores de ask1 |
Country Status (22)
Country | Link |
---|---|
US (2) | US11814362B2 (es) |
EP (1) | EP3814333A1 (es) |
JP (1) | JP2021528456A (es) |
KR (1) | KR20210024532A (es) |
CN (1) | CN112638896A (es) |
AR (1) | AR115636A1 (es) |
AU (1) | AU2019291806A1 (es) |
BR (1) | BR112020026423A2 (es) |
CA (1) | CA3104662A1 (es) |
CL (1) | CL2020003375A1 (es) |
CO (1) | CO2021000782A2 (es) |
CR (1) | CR20210049A (es) |
EA (1) | EA202190034A1 (es) |
IL (1) | IL279709A (es) |
JO (1) | JOP20200318A1 (es) |
MA (1) | MA53009A (es) |
MX (1) | MX2020013895A (es) |
PE (1) | PE20211379A1 (es) |
SG (1) | SG11202012784SA (es) |
TW (1) | TW202035389A (es) |
UY (1) | UY38278A (es) |
WO (1) | WO2020006031A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210024586A (ko) | 2018-06-27 | 2021-03-05 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
TWI598347B (zh) * | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
UY35212A (es) * | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
WO2015095059A1 (en) * | 2013-12-20 | 2015-06-25 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitors |
WO2018151830A1 (en) | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Pyridinyl based apoptosis signal-regulation kinase inhibitors |
-
2019
- 2019-06-26 KR KR1020217000614A patent/KR20210024532A/ko unknown
- 2019-06-26 AR ARP190101780A patent/AR115636A1/es unknown
- 2019-06-26 TW TW108122356A patent/TW202035389A/zh unknown
- 2019-06-26 BR BR112020026423-7A patent/BR112020026423A2/pt not_active Application Discontinuation
- 2019-06-26 AU AU2019291806A patent/AU2019291806A1/en not_active Abandoned
- 2019-06-26 SG SG11202012784SA patent/SG11202012784SA/en unknown
- 2019-06-26 JP JP2020572645A patent/JP2021528456A/ja active Pending
- 2019-06-26 EA EA202190034A patent/EA202190034A1/ru unknown
- 2019-06-26 MX MX2020013895A patent/MX2020013895A/es unknown
- 2019-06-26 EP EP19739494.3A patent/EP3814333A1/en active Pending
- 2019-06-26 WO PCT/US2019/039156 patent/WO2020006031A1/en unknown
- 2019-06-26 CN CN201980042586.9A patent/CN112638896A/zh active Pending
- 2019-06-26 UY UY0001038278A patent/UY38278A/es not_active Application Discontinuation
- 2019-06-26 MA MA053009A patent/MA53009A/fr unknown
- 2019-06-26 JO JOP/2020/0318A patent/JOP20200318A1/ar unknown
- 2019-06-26 PE PE2020002138A patent/PE20211379A1/es unknown
- 2019-06-26 US US17/253,269 patent/US11814362B2/en active Active
- 2019-06-26 CR CR20210049A patent/CR20210049A/es unknown
- 2019-06-26 CA CA3104662A patent/CA3104662A1/en not_active Abandoned
-
2020
- 2020-12-23 CL CL2020003375A patent/CL2020003375A1/es unknown
- 2020-12-23 IL IL279709A patent/IL279709A/en unknown
-
2021
- 2021-01-25 CO CONC2021/0000782A patent/CO2021000782A2/es unknown
-
2023
- 2023-10-05 US US18/377,125 patent/US20240109867A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CO2021000782A2 (es) | 2021-01-29 |
CN112638896A (zh) | 2021-04-09 |
TW202035389A (zh) | 2020-10-01 |
PE20211379A1 (es) | 2021-07-27 |
JP2021528456A (ja) | 2021-10-21 |
IL279709A (en) | 2021-03-01 |
SG11202012784SA (en) | 2021-01-28 |
JOP20200318A1 (ar) | 2020-12-10 |
WO2020006031A1 (en) | 2020-01-02 |
CA3104662A1 (en) | 2020-01-02 |
US20210115020A1 (en) | 2021-04-22 |
CR20210049A (es) | 2021-07-01 |
EP3814333A1 (en) | 2021-05-05 |
CL2020003375A1 (es) | 2021-09-03 |
AR115636A1 (es) | 2021-02-10 |
US20240109867A1 (en) | 2024-04-04 |
EA202190034A1 (ru) | 2021-04-08 |
AU2019291806A1 (en) | 2021-01-07 |
US11814362B2 (en) | 2023-11-14 |
KR20210024532A (ko) | 2021-03-05 |
BR112020026423A2 (pt) | 2021-03-23 |
MX2020013895A (es) | 2021-07-21 |
WO2020006031A8 (en) | 2020-09-24 |
MA53009A (fr) | 2021-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20160140A (es) | Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih | |
CU20210015A7 (es) | COMPUESTOS DE PIRAZOLO [3.4-b] PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET | |
NI201900013A (es) | Inhibidor de piridopirimidinona cdk2/4/6 | |
UY37900A (es) | Nuevos derivados de rapamicina | |
ECSP21034668A (es) | Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cáncer | |
CR20190168A (es) | Compuestos de benzo[b]tiofeno como agonistas de sting | |
CU20180152A7 (es) | Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2 | |
CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
NI201600166A (es) | Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso para tratar cáncer | |
CR20160287A (es) | Inhibidores de syk | |
UY36244A (es) | Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen | |
CL2015002520A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso. | |
AR094964A1 (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd) | |
DOP2019000140A (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
SV2017005354A (es) | Derivados de quinolizinona como inhibidores de pi3k | |
CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
DOP2015000214A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
UY39517A (es) | Inhibidores de la btk | |
ECSP16083017A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
CO2021000782A2 (es) | Agentes inhibidores de ask1 | |
DOP2021000223A (es) | DERIVADOS DE 1,1-DIÓXIDO DE 3-AMINO-4H-BENZO[E][1,2,4] tiadiazina COMO INHIBIDORES DE MRGX2 | |
CO2021003218A2 (es) | Agentes inhibidores de ask1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20240522 |